Repligen (NASDAQ:RGEN) Stock Price Up 10.1% – Here’s What Happened

Repligen Corporation (NASDAQ:RGEN)’s stock price traded up 10.1% on Wednesday . The company traded as high as $139.50 and last traded at $139.1240. 445,146 shares traded hands during trading, a decline of 53% from the average session volume of 956,611 shares. The stock had previously closed at $126.37.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on RGEN shares. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. HC Wainwright increased their price target on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. HSBC cut their price target on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. Finally, Roth Mkm began coverage on shares of Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.64.

Repligen Stock Performance

The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average price is $122.54 and its 200 day moving average price is $135.46. The firm has a market capitalization of $8.21 billion, a PE ratio of 160.23, a PEG ratio of 2.67 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, research analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current year.

Institutional Trading of Repligen

Several large investors have recently made changes to their positions in RGEN. Avidity Partners Management LP lifted its holdings in Repligen by 54.7% in the 1st quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares during the last quarter. Glenmede Trust Co. NA grew its position in Repligen by 10.3% in the 1st quarter. Glenmede Trust Co. NA now owns 8,268 shares of the biotechnology company’s stock worth $974,000 after purchasing an additional 770 shares during the last quarter. Summitry LLC increased its holdings in shares of Repligen by 37.0% during the 1st quarter. Summitry LLC now owns 2,385 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 644 shares during the period. Segall Bryant & Hamill LLC raised its position in shares of Repligen by 5.5% during the first quarter. Segall Bryant & Hamill LLC now owns 155,025 shares of the biotechnology company’s stock valued at $18,265,000 after buying an additional 8,045 shares during the last quarter. Finally, Amundi lifted its stake in shares of Repligen by 7.0% in the first quarter. Amundi now owns 44,959 shares of the biotechnology company’s stock valued at $5,297,000 after buying an additional 2,925 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.